ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.…
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
ADMA Biologics (NASDAQ: ADMA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 640 employees.
The shares were at 13.17 USD on 20 November 2026, down 13.8% over 52 weeks. Its 52-week range is 7.210 USD to 20.46 USD: the price is 35.6% below the high and 82.7% above the low.
At a market capitalisation of 2.92B USD, it trades at 17.1 times trailing earnings and 14.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 48% for ADMA.
ADMA Biologics reports return on equity of 30.8%, an operating margin of 44.9% and revenue up 5.1% year over year.
Its debt exceeds its cash by 78.25M USD, a debt-to-equity ratio of 0.17. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 18.00 USD is 36.7% above the current price. The next earnings report is expected on 24 February 2027.